Barriers to physical activity in patients with pulmonary hypertension

Thomas M. Cascino¹, Vallerie V. McLaughlin¹, Caroline R. Richardson², Nilofar Behbahani-Nejad³, Victor M. Moles¹, Scott H. Visovatti¹ and Elizabeth A. Jackson⁴

¹Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA; ²Department of Family Medicine, University of Michigan, Ann Arbor, MI, USA; ³Oakland University William Beaumont School of Medicine, Auburn Hills, MI, USA; ⁴Division of Cardiovascular Medicine, University of Alabama at Birmingham, Birmingham, AL, USA

Abstract

Patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) have low levels of physical activity (PA). Increased PA has health benefits including improved quality of life. This study aimed to identify patient-perceived barriers to PA that correlate with objectively measured PA in this population. We performed a cross-sectional survey of 40 patients with PAH and CTEPH. Participants rated how often 15 barriers interfere with being physically active on a 5-point Likert Scale. The primary outcome measure was PA quantified using the Fitbit Zip activity tracker for two weeks. The primary independent variables were the 15 barriers and a summary score (total average barriers). Separate multivariable linear regressions were performed to assess the association between the 15 barriers and the summary score and PA adjusting for age, sex, and PAH etiology. Of the participants, 85% (34/40) had valid step counts and were included. Of these 34, 85% (n = 29) were female and 91% (n = 31) had PAH. The median (interquartile range [IQR]) number of daily steps was 3913 (2309–6313). The barriers endorsed most strongly were lack of self-discipline, lack of energy, and lack of interest. In the multivariable analysis, a 1-unit increase in perceived lack of interest, lack of enjoyment, and skill development was associated with a significant decrease in step counts of -1414 steps (95% confidence interval [CI] = (-12580 to -248)), -1458 steps (-2404 to -51), and -1533 steps (-2910 to -156), respectively. Counseling and interventions aimed at increasing PA in patients with PAH should address interest, enjoyment, and skill development.

Keywords

Exercise capacity, barriers, motivation

Date received: 1 January 2019; accepted: 23 March 2019

Pulmonary Circulation 2019; 9(2) 1–8 DOI: 10.1177/2045894019847895

Patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) have low levels of physical activity (PA) and low health-related quality of life (HRQOL)¹ with increased sedentary time and reduced PA compared to controls.¹⁻³ The overall benefits of PA in the management of a diverse range of cardiovascular diseases is well established.⁴ Lower PA has recently been shown to be associated with worse patient-reported symptoms in patients with PAH.¹⁻⁵ This has led to an interest in treatments aimed at increasing the daily PA of patients with pulmonary hypertension (PH) to improve functional status and HRQOL.⁶

Current PH guidelines recommend encouraging PA while avoiding distressing symptoms or excessive exertion.⁷⁻⁸ Interventions aimed at increasing PA have largely focused on the pharmacological management of PH or structured exercise therapy.⁹ While improved use of these therapies has the potential to increase PA, there are likely additional personal and environmental barriers that exist, similar to the...
general adult population. An improved understanding of perceived barriers for patients with PH becomes critical in developing interventions aimed at increasing PA.

Accordingly, the purpose of the study was to identify patient-perceived barriers to PA in patients with PH. We hypothesized that patient-perceived barriers to PA would correlate with objectively measured PA.

**Methods**

**Study design**

We performed a cross-sectional study of patients with PAH and CTEPH. Participants were recruited from the University of Michigan Medical Center pulmonary hypertension clinic between June 2016 and November 2016 as part of a more extended prospective study designed to explore long-term associations between PA and quality of life. The study was approved by the University of Michigan Institutional Review Board and written informed consent was obtained from all patients (HUM00110649).

**Participants**

We enrolled patients aged ≥18 years who had a diagnosis of PAH or CTEPH by right heart catheterization according to World Health Organization (WHO) Criteria, and a stable PAH-specific medication regimen for at least three months. Participants were excluded if they had a life expectancy <1 year, co-morbidities which limit physical activity to a severe degree (e.g. wheelchair-bound), current uncontrolled psychiatric disease, active substance abuse, concurrent enrollment in pulmonary rehabilitation, or current pregnancy.

**Measures**

Basic demographic characteristics including age, sex, co-morbid conditions, medications, WHO FC, and 6-min walk distance (6MWD) at the time of enrollment were ascertained from review of the medical record. All participants completed a 6-min walk test in a standardized manner by trained personal consistent with the American Thoracic Society guidelines.

**Primary outcome**

Average daily PA was measured using the Fitbit Zip™ accelerometer over the course of two weeks. The Fitbit Zip™ is a commercially available device that can be attached to the participant’s waistband, belt, shirt, or wrist. The device has been shown to reliably and validly measure activity in free-living conditions. Participants were instructed to continue their usual level of activity while wearing the pedometer during waking hours. Participants were specifically not given step count goals or PA outputs. Reactivity, the change in a person’s PA after beginning to use a pedometer, was assessed and found not to be present. Thus, the two-week PA monitoring period began on the day of enrollment. Daily and weekly step counts were included in the analysis if the participant walked ≥200 steps on at least 4/7 days during the week. The lower limit of 200 steps was selected after inspection of the raw data and was 2 SD below the mean daily step count for the participants. For descriptive purposes, the participants were classified into “low” if below, or “high” if above, the median average daily step count for the cohort.

**Assessment of barriers to physical activity**

Perceived barriers to exercise and PA were assessed with a 15-item questionnaire of established barriers described by Salis, et al. in the general population and rated on a 5-point Likert scale in the range of “1 = never” to “5 = very often.” Participants were asked how often each barrier interfered with, or prevented them from, exercising or being physically active. The internal consistency was high with a Cronbach’s alpha of 0.92. In order to assess overall barriers to PA, the total barriers score was determined from the average of the 15 barriers.

**Statistical analysis**

Participant demographic characteristics, 6MWD, PA level, and barriers were collected as frequencies for categorical variables and means for continuous variables. Baseline characteristics and univariable analysis of patient-perceived barriers were analyzed according to PA level (based on median step count) using Wilcoxon rank-sum test for continuous variables and Pearson’s chi-squared test for categorical variables. Step counts between weeks 1 and 2 compared with a paired t-test. The frequency of a barrier reported as “often” or “very often” was determined.

The association between patient perceived barriers and PA as a continuous variable was evaluated with unadjusted and adjusted linear regression. For all estimated models, the dependent variable was PA, quantified as the average daily step count. Separate regressions were performed with each patient-perceived barrier as the primary independent variable. A final model was done using the total average barriers score as the primary dependent variable. All models were adjusted for age, sex, and etiology of PH in the multivariable analysis. Etiology of PH was adjusted for as scleroderma-associated PAH has previously been associated with lower levels of PA. Regression coefficients representing the change in average daily step counts per a 1-unit increase in barriers (e.g. going from “never” to “rarely”) were generated. Using the final linear regression models, estimations of the marginal mean effect of perceived barriers on PA, adjusting for age, sex, and etiology of PH, were estimated using the Stata (v15) margins command. After completion of the primary analysis, an exploratory analysis...
was performed with sub-maximal exercise testing (6MWD) as the dependent variable given the prior described association between average daily step counts and 6MWD. A P value <0.5 was used to determine statistical significance. Analyses were conducted using STATA 15 (College Station, TX, USA).

Results

In total, 40 participants were enrolled. Of the 40 participants, 34 (85%) had valid step counts and were included in the analysis. Participant demographic and clinical characteristics are listed in Table 1. The majority of the participants had PAH (n=31, 91%) that was either idiopathic (n=13, 38%) or associated with connective tissue disease (n=15, 44%) and were female (n=29, 85%) with a mean age (±SD) of 61 (± 12). The median step count for the cohort was 3913 (interquartile range [IQR] =2309–6313) steps. Step counts in weeks 1 and 2 were similar (mean difference = 220 steps, 95% confidence interval [CI]=−346–788, P value >0.20). When looking at the characteristics of the cohort, the average age, race/ethnicity, and vital signs were similar between participants grouped by activity level (Table 1). Notable differences between the groups included lower BMI and better 6MWD in the high activity group and more connective-tissue disease associated PAH, worse FC, and increased diuretic use in the low activity group.

The top three barriers cited by participants were lack of self-discipline, lack of energy, and lack of interest in exercise (Table 2). In addition to lack of self-discipline and lack of energy, lack of enjoyment from exercise and lack of good health were the most commonly cited barriers that “often” or “very often” interfered with PA for the cohort (Fig. 1). Lack of skills and fear of injury did not “often” interfere with PA for participants in the cohort.

Perceived barriers differed by activity level among patients in the low versus high activity group (Table 2). Participants in the low activity group reported a higher average summary barrier score (P=0.045) and higher average scores for several barriers including lack of interest in exercise, lack of enjoyment from exercise, and lack of self-discipline. There were trends toward more reported lack of skills and discouragement from exercise.

After adjusting for age, sex, and etiology of PH, several barriers remained associated with lower PA (as a continuous outcome) including lack of interest in exercise, lack of enjoyment from exercise, and lack of skills for exercise (Table 3). The summary barriers score was no longer significantly associated with PA (P value =0.076). For every 1-unit increase in the reported perceived lack of interest in exercise, lack of enjoyment from exercise, and lack of skills for exercise, the associated decrease in step counts was -1414 steps (95% CI =−2580 – −248), −1458 steps (95% CI =−2404 – −511), and −1533 steps (95% CI =−2910 – −156), respectively. The predicted average daily step counts in the multivariable model by the frequency of a barrier for lack of interest, lack of enjoyment, and lack of skill are shown in Fig. 2. Participants who reported “never” experiencing a lack of interest in exercise or lack of enjoyment in exercise had a predicted average daily step count of >6700 steps compared to <2500 steps among participants who “often” experienced these barriers. In the exploratory multivariable analysis, both lack of knowledge (beta coefficient = −43, 95% CI =−82 – −34) and lack of skills (beta coefficient = −58, 95% CI =−101 – −15) was associated with reduced 6MWD.

Discussion

In this cross-sectional study of participants with PAH and CTEPH, we investigated the association of patient-perceived barriers on PA. Internal barriers, or barriers as a result of one’s own beliefs and decisions, were most commonly reported as interfering with PA or exercise regardless of activity level. The most commonly cited reasons included lack of self-discipline, lack of energy, and lack of interest. Higher perceived lack of enjoyment, lack of interest, and lack of skills were associated with low PA after adjusting for known predictors of PA.

The health benefits of regular daily exercise and PA are well established. PA is a known, modifiable risk factor for heart disease and has been identified as a core health behavior that contributes to cardiovascular health by the American Heart Association. Recent guidelines stress the necessity of focusing on subgroups of the population because of the unique impact of diseases on PA. The current PH guidelines recognize this and recommend encouraging PA while avoiding distressing symptoms or excessive exertion. Despite the proven benefits of PA, patients with PH remain sedentary. Participants in our study walked far fewer steps compared to most adults in the United States. Importantly, lower daily PA in patients with PH has been shown to be associated with worse patient-reported symptoms and interventions targeting PA are being considered as a therapeutic goal in the treatment of PH.

The best way to optimize PA in patients with PH is unclear, though a combination of targeted pharmacological therapies, structured exercise, and application of behavioral change theory are likely to result in increases. Determinants of PA are complex and differ between populations of patients. PA levels are an interplay of not only the individual and their medical conditions but are also impacted by social, environmental, and policy contributions. Importantly, the identification of barriers has been found to be associated with an increased impact of interventions aimed at increasing PA. As a result, understanding the correlations of patient-perceived barriers and PA is a necessary first step toward optimizing PA.

In our study of participants with PH, the individual or internal barriers, rather than external barriers, correlated with PA levels. Broadly examining the inherent satisfaction participants obtain from PA, these internal patient factors
have been shown to impact motivation for exercise in diverse populations with chronic cardiac disease. Strategies seeking to encourage increased PA need to acknowledge this and consider interventions that increase intrinsic motivation and promote participant enjoyment. One such strategy to improve PA that has been shown to be effective is to focus on these intrinsic motivations rather than just emphasizing the health benefits of PA. The optimal scenario will include individualized tailoring of the PA plan and/or interventions in trials focused on skill improvement, personal accomplishment, and excitement while performing PA. Additionally, in the exploratory analysis, similar barriers were associated with decreased sub-maximal exercise capacity (6MWD) suggesting that strategies that increase PA may be associated with changes in this well-established outcome.

### Table 1. Baseline characteristics grouped by PA level.

| Characteristics                           | Total (n = 34) | High activity (n = 17) | Low activity (n = 17) | P value |
|------------------------------------------|---------------|------------------------|-----------------------|---------|
| Age (years) (mean (SD))                  | 61 (12)       | 59 (13)                | 63 (11)               | 0.32    |
| Female                                   | 29 (85)       | 13 (76)                | 16 (94)               | 0.15    |
| Race                                     |               |                        |                       |         |
| Black                                    | 4 (12)        | 2 (12)                 | 2 (12)                | 1.00    |
| White                                    | 27 (79)       | 14 (82)                | 13 (76)               |         |
| Not reported                             | 3 (9)         | 1 (6)                  | 2 (12)                |         |
| BMI (kg/m²) (mean (SD))                  | 28 (5)        | 25 (3)                 | 31 (6)                | 0.001   |
| SBP (mmHg) (mean (SD))                   | 123 (19)      | 119 (18)               | 127 (20)              | 0.23    |
| DBP (mmHg) (mean (SD))                   | 64 (9)        | 65 (9)                 | 64 (9)                | 0.98    |
| HR (BPM) (mean (SD))                     | 78 (16)       | 76 (16)                | 81 (16)               | 0.34    |
| PH type                                  |               |                        |                       | 0.013   |
| PAH                                      |               |                        |                       |         |
| Idiopathic                               | 13 (38)       | 9 (53)                 | 4 (24)                |         |
| Heritable                                | 1 (3)         | 1 (6)                  | 0 (0)                 |         |
| CTD                                      | 15 (44)       | 3 (18)                 | 12 (71)               |         |
| Portal hypertension                      | 1 (3)         | 1 (6)                  | 0 (0)                 |         |
| CHD                                      | 1 (3)         | 1 (6)                  | 0 (0)                 |         |
| CTEPH                                    | 3 (9)         | 2 (12)                 | 1 (6)                 |         |
| WHO FC                                   |               |                        |                       | 0.035   |
| Class I                                  | 5 (15)        | 4 (24)                 | 1 (6)                 |         |
| Class II                                 | 21 (62)       | 12 (71)                | 9 (53)                |         |
| Class III                                | 8 (24)        | 1 (6)                  | 7 (41)                |         |
| Steps per day (mean (SD))                | 4650 (3246)   | 6962 (3052)            | 2337 (1027)           | <0.001  |
| 6MWD (m) (mean (SD))                     | 465 (115)     | 548 (74)               | 378 (79)              | <0.001  |
| Medications                              |               |                        |                       |         |
| Prostacyclins                            | 15 (44)       | 8 (47)                 | 7 (41)                | 1.00    |
| ERA                                      | 18 (53)       | 9 (53)                 | 9 (53)                | 1.00    |
| PDE-5 inhibitor                          | 23 (68)       | 11 (65)                | 12 (71)               | 0.71    |
| sGC                                      | 2 (6)         | 1 (6)                  | 1 (6)                 | 1.00    |
| Diuretic                                 | 24 (71)       | 9 (53)                 | 15 (88)               | 0.024   |
| Anticoagulation                          | 14 (41)       | 9 (53)                 | 5 (29)                | 0.16    |
| Aspirin                                  | 8 (24)        | 1 (6)                  | 7 (41)                | 0.015   |
| CCB                                      | 7 (21)        | 3 (18)                 | 4 (24)                | 0.67    |
| BB                                       | 1 (3)         | 0 (0)                  | 1 (6)                 | 0.31    |
| Spironolactone                           | 4 (12)        | 2 (12)                 | 2 (12)                | 1.00    |

Values are presented n (%) unless otherwise indicated.

SD, standard deviation; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; BPM, beats per minute; PH, pulmonary hypertension; PAH, pulmonary arterial hypertension; CTD, connective tissue disease; CHD, congenital heart disease; CTEPH, chronic thromboembolic disease; WHO, World Health Organization; FC, functional class; 6MWD, 6-min walk distance; ERA, endothelin receptor antagonist; PDE-5, phosphodiesterase type 5; sGC, soluble guanylyl cyclase.
Interestingly, total average barriers and external barriers including environmental factors such as lack of equipment, poor weather, and lack of time did not correlate with reduced PA in our study. While total average barriers showed a trend toward an association, this was not statistically significant. We suspect our study did not have adequate power to identify a difference though this will need to be confirmed in future studies. With regard to external barriers, prior work in different patient populations has shown a large impact of the social and physical environment on PA.23 There are several possible explanations for this finding. It is recognized that population subgroups experience different barriers that impact PA.18 Older adults have previously been shown to be impacted more by environmental variables and the relatively younger age of patients with PH may explain the lack of an association between environmental barriers and PA.29 Additionally, how PA is measured could influence the results. A strength of the study that differentiates it from much of the prior work was the use of activity trackers to objectively measure activity.23 It is possible that if patient-reported PA

### Table 2. Patient perceived barriers to PA.

| Barriers (mean (SD)) | Total (n = 34) | “High activity” (n = 17) | “Low activity” (n = 17) | P value |
|----------------------|---------------|-------------------------|------------------------|---------|
| Lack of interest in exercise | 2.5 (0.93) | 2.1 (0.9) | 2.9 (0.78) | 0.02 |
| Lack of enjoyment from exercise | 2.4 (1) | 1.9 (0.86) | 3 (0.94) | 0.01 |
| Lack of self-discipline | 2.8 (1.2) | 2.3 (1.2) | 3.3 (1.2) | 0.03 |
| Lack of company | 2.2 (1.1) | 1.9 (0.97) | 2.4 (1.1) | 0.20 |
| Lack of knowledge on how to exercise | 1.6 (0.85) | 1.4 (0.71) | 1.9 (0.93) | 0.11 |
| Lack of skills | 1.6 (0.77) | 1.4 (0.71) | 1.9 (0.78) | 0.08 |
| Discouragement | 2 (0.95) | 1.7 (0.85) | 2.3 (0.99) | 0.08 |
| Lack of equipment | 1.8 (1.1) | 1.5 (0.8) | 2.1 (1.3) | 0.17 |
| Self-conscious about my looks when I exercise | 1.6 (0.95) | 1.4 (0.8) | 1.8 (1.1) | >0.20 |
| Fear of injury | 1.9 (0.86) | 1.8 (0.83) | 1.9 (0.9) | >0.20 |
| Lack of energy | 2.6 (1.2) | 2.4 (1.2) | 2.8 (1.3) | >0.20 |
| Lack of facilities | 1.9 (1) | 1.7 (0.92) | 2.2 (1.1) | 0.18 |
| Lack of good weather | 2.4 (1.1) | 2.2 (0.97) | 2.6 (1.3) | >0.20 |
| Lack of time | 2.2 (1.1) | 2.4 (1.3) | 2 (0.94) | >0.20 |
| Lack of good health | 2.4 (1.1) | 2.4 (0.81) | 2.4 (1.3) | >0.20 |
| Total average barriers | 2.1 (0.68) | 1.9 (0.6) | 2.4 (0.68) | <0.05 |

Mean patient perceived barriers to PA grouped by activity level. P value for bivariate analysis.

![Fig. 1. Percentage of participants reporting barrier interferes “often” or “very often.”](image-url)
were used, the associations would change. Regardless, confirming the lack of an impact of external barriers on PA in patients with PH with longitudinal data has important trial design and policy implications.

There are limitations of our study worth discussing. Our participants were enrolled at a single, academic center and may not be representative of the general PH population. The comparatively large sample size for a study of ambulatory PA monitoring does alleviate this concern to a degree.\(^1\)\(^-\)\(^3\) This was a cross-sectional analysis that is unable to address causality. However, much of the initial work on barriers to PA in other disciplines has been cross-sectional\(^2\)\(^3\) as it lays the foundation for future work. Being an observational study, the impact of confounding must always be considered. We did adjust for PAH etiology, an established risk factor for low PA.\(^5\) We were unable to adjust for additional potential confounders because of sample size limitations. As mentioned, though the sample size is small, it is comparable to studies that have objectively measured PA.\(^1\)\(^-\)\(^3\) Lastly, 15% of participants did not have valid step counts for the two-week period. While this is similar to the recently completed Electronic Activity Level Monitoring Pilot in Pulmonary Hypertension study,\(^3\)\(^0\) a better understanding of barriers to PA monitoring among patients with PH is necessary. A recently completed home exercise pilot study suggests that scheduled verbal communication may improve adherence in future studies.\(^3\)\(^1\)

These findings have important implications in the understanding of PA levels in patients with PH and the design of future intervention trials. For a clinician currently caring for

### Table 3. Results of multivariable logistic regression reporting Beta coefficient for step count.

| Barrier                                              | Beta coefficient (95% CI) | P value |
|------------------------------------------------------|---------------------------|---------|
| Lack of interest in exercise                         | -1414 (-2580 – -248)      | 0.019   |
| Lack of enjoyment from exercise                      | -1458 (-2404 – -511)      | 0.004   |
| Lack of self-discipline                              | -473 (-1393 – 520)        | >0.20   |
| Lack of company                                      | -405 (-1463 – 653)        | >0.20   |
| Lack of knowledge on how to exercise                 | -940 (-2202 – 332)        | 0.138   |
| Lack of skills                                       | -1533 (-2910 – -156)      | 0.030   |
| Discouragement                                       | -744 (-1888 – 399)        | 0.193   |
| Lack of equipment                                    | -330 (-1395 – 736)        | >0.20   |
| Self-conscious about my looks when I exercise        | -701 (-1884 – 482)        | >0.20   |
| Fear of injury                                       | -346 (-1653 – 960)        | >0.20   |
| Lack of energy                                       | -576 (-1558 – 405)        | >0.20   |
| Lack of facilities                                   | -584 (-1737 – 570)        | >0.20   |
| Lack of good weather                                 | -719 (-1654 – 216)        | 0.127   |
| Lack of time                                         | -55 (-1164 – 1054)        | >0.20   |
| Lack of good health                                  | -474 (-1641 – 692)        | >0.20   |
| Total average barriers                               | -1468 (-3101 – 164)       | 0.076   |

Beta coefficient represents associated change in daily step counts per 1-unit increase in barrier adjusted for age, sex, and PAH etiology.
patients with PH, these findings emphasize the need to understand a patient’s internal barriers and design individual PA plans to make PA a habit. Tailoring an exercise plan could have a profound impact on PA if addressing barriers increases activity as previously shown. For example, if a patient reported not enjoying PA, one could counsel the patient on finding an activity they enjoy such as going for a bike ride with friends. Given the associated increase in PA by almost 1500 steps when a barrier was reduced (Fig. 2), this would be well above the minimal important difference of 600–1100 steps described in studies of pulmonary rehabilitation for chronic lung disease. In regards to trial design, future interventional studies aimed at increasing PA should recognize that a one-size-fits-all approach may not be the most efficacious. While increasing access to proven therapies such as pulmonary rehabilitation programs will improve PA, future work aimed at optimizing PA in patients with PH should include multidimensional interventions that consider the potential impact of intrinsic barriers. Including patients in the design of such work through qualitative or mixed-methods research has the potential to maximize motivation. In the meantime, identifying and addressing the intrinsic barriers with an individualized plan has significant potential while waiting for completion of studies aimed at increasing PA.

In conclusion, several barriers including lack of self-discipline, lack of energy, and lack of interest are the most commonly cited reasons preventing increased exercise and PA. Barriers related to enjoyment, interest, and skills were associated with PA levels. Personalized regimens that address these barriers have the opportunity to increase PA though additional research is needed to determine causality.

Conflict of interest
The author(s) declare the following conflicts of interest: VVMcL has served as a consultant and/or advisor for Actelion Pharmaceuticals US, Inc., Bayer, Gilead Sciences, Inc., Medtronic, Merck, St. Jude Medical, and United Therapeutics Corporation. The University of Michigan has received research funding from Actelion Pharmaceuticals US, Inc., Arena, Bayer, and Sonovie. The other authors declare no conflicts of interest.

Funding
TMC was supported by a National Institutes of Health T32 post-doctoral research training grant (T32-HL007853). This project was partially funded by a Michigan Medicine Frankel Cardiovascular Center Micro Grant.

ORCID iD
Scott H. Visovatti https://orcid.org/0000-0002-4595-1657

References
1. Matura LA, Shou H, Fritz JS, et al. Physical activity and symptoms in pulmonary arterial hypertension. Chest 2016; 150: 46–56.
2. Mainguy V, Provencher S, Maltais F, et al. Assessment of daily life physical activities in pulmonary arterial hypertension. PLoS One 2011; 6: e27993.
3. Pugh ME, Buchowski MS, Robbins IM, et al. Physical activity limitation as measured by accelerometry in pulmonary arterial hypertension. Chest 2012; 142: 1391–1398.
4. Lobelo F, Rohm Young D, Sallis R, et al. Routine assessment and promotion of physical activity in healthcare settings: a scientific statement from the American Heart Association. Circulation 2018; 137: e495–e522.
5. Okumus G, Aslan GK, Arseven O, et al. The role of an activity monitor in the objective evaluation of patients with pulmonary hypertension. Clin Respir J 2018; 12: 119–125.
6. Richter MJ, Grimminger J, Kruger B, et al. Effects of exercise training on pulmonary hemodynamics, functional capacity and inflammation in pulmonary hypertension. Pulm Circ 2017; 7: 20–37.
7. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573–1619.
8. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46: 903–975.
9. Galié N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62: D60–72.
10. Salmon J, Owen N, Crawford D, et al. Physical activity and sedentary behavior: a population-based study of barriers, enjoyment, and preference. Health Psychol 2003; 22: 178–188.
11. McLaughlin VV and McGoon MD. Pulmonary arterial hypertension. Circulation 2006; 114: 1417–1431.
12. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111–117.
13. Kooiman TJ, Dontje ML, Sprenger SR, et al. Reliability and validity of ten consumer activity trackers. BMC Sports Sci Med Rehabil 2015; 7: 24.
14. Clemes SA, Matchett N and Wane SL. Reactivity: an issue for short-term pedometer studies? Br J Sports Med 2008; 42: 68–70.
15. Sallis JF, Hovell MF, Hofstetter CR, et al. A multivariate study of determinants of vigorous exercise in a community sample. Prev Med 1989; 18: 20–34.
16. Korkiakangas EE, Alahuhta MA and Laitinen JH. Barriers to regular exercise among adults at high risk or diagnosed with type 2 diabetes: a systematic review. Health Promot Int 2009; 24: 416–427.
17. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2018 update: A report from the American Heart Association. Circulation 2018; 137: e67–e492.
18. U.S. Department of Health and Human Services. Physical Activity Guidelines for Americans. 2nd ed. Washington, DC: U.S. Department of Health and Human Services, 2018.

19. Tudor-Locke C, Johnson WD and Katzmarzyk PT. Accelerometer-determined steps per day in US adults. Med Sci Sports Exerc 2009; 41: 1384–1391.

20. McLaughlin V, Bacchetta M, Badesch D, et al. Update on pulmonary arterial hypertension research: proceedings from a meeting of experts. Curr Med Res Opin 2018; 34: 263–273.

21. Blaney JM, Lowe-Strong A, Rankin-Watt J, et al. Cancer survivors’ exercise barriers, facilitators and preferences in the context of fatigue, quality of life and physical activity participation: a questionnaire-survey. Psycho-oncology 2013; 22: 186–194.

22. Craike M, Hose K and Livingston PM. Physical activity participation and barriers for people with multiple myeloma. Support Care Cancer 2013; 21: 927–934.

23. Bauman AE, Reis RS, Sallis JF, et al. Correlates of physical activity: why are some people physically active and others not? Lancet 2012; 380: 258–271.

24. French DP, Olander EK, Chisholm A, et al. Which behaviour change techniques are most effective at increasing older adults’ self-efficacy and physical activity behaviour? A systematic review. Ann Behav Med 2014; 48: 225–234.

25. Teixeira PJ, Carraca EV, Markland D, et al. Exercise, physical activity, and self-determination theory: a systematic review. Int J Behav Nutr Phys Act 2012; 9: 78.

26. Santauralia N and Jaarsma T. What motivational factors influence exercise in cardiac patients? A literature review. European Journal of Preventive Medicine 2013; 1: 1–20.

27. Hoare E, Stavreski B, Jennings GL, et al. Exploring motivation and barriers to physical activity among active and inactive Australian adults. Sports (Basel) 2017; 5: 47.

28. Silva MN, Markland D, Vieira PN, et al. Helping overweight women become more active: Need support and motivational regulations for different forms of physical activity. Psychology of Sport and Exercise 2010; 11: 591–601.

29. Sallis JF, King AC and Sirard JR. Perceived environmental predictors of physical activity over 6 months in adults: activity counseling trial. Health Psychol 2007; 26: 701–709.

30. Bayer. (e-MOTION PH) electronic - Activity Level Monitoring Pilot in Pulmonary Hypertension. 2017.

31. Brown MB, Kempf A, Collins CM, et al. A prescribed walking regimen plus arginine supplementation improves function and quality of life for patients with pulmonary arterial hypertension: a pilot study. Pulm Circ 2018; 8: 2045893217743966.

32. Giroir BP and Wright D. Physical activity guidelines for health and prosperity in the United States. JAMA 2018; 320: 1971–1972.

33. Demeyer H, Burtn C, Hornikx M, et al. The minimal important difference in physical activity in patients with COPD. PLoS One 2016; 11: e0154587.

34. Tariq S and Woodman J. Using mixed methods in health research. JRSM Short Rep 2013; 4: 2042533313479197.